Enhancing Panic and Smoking Reduction Treatment with D-Cycloserine

Eligibility Criteria

Male and female patients ages 18-65:

  • Daily smoker for at least one year
  • Currently smokes an average of at least 8 cigarettes per day
  • Reports a motivation to quit smoking in the next month
  • Evidence of panic attack within the past year and endorsement of smoking as an emotion regulation strategy
Exclusion Criteria
  • Subjects who do not use smoking as an emotion regulation strategy
  • Current diagnosis of a psychotic, eating, developmental or bipolar disorder
  • Significant suicide risk as determined by structured interview
  • Pregnant women, lactating women, and women of childbearing postential who are not using medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months)
  • Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 6 months
  • Current use of isoniazid or ethionamide compounds
  • A history of significant medical condition and/or be deemed as currently unhealthy in the context of a complete physical examination
  • Limited mental competency and the inability to give informed, voluntary, written consent to participate
  • Current use of any pharmacotherapy or psychotherapy for smoking cessation not provided by the researchers during the quit attempt
  • Concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment or anxiety or mood disorder other than general supportive therapy initiated at least 3 months prior to study
  • Use of other tobacco products
  • Plans to move (outside the immediate area) in the next 6 months
  • Insufficient command of the English language
State
Texas

The purpose of the current study is to evaluate the efficacy of d-cycloserine in augmenting treatment of smoking cessation for individuals with panic attacks. Individuals will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill of d-cycloserine (DCS) or one pill placebo one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).

Reliability and Validity of a Structured Interview for Anxiety, Mood, and OCD and Related Disorders

Eligibility Criteria
  • Adults age 18 and older
  • Those experiencing symptoms of body dysmorphic disorder, skin picking disorder, trichotillomania, or agoraphobia.

 

Exclusion Criteria
  • Children younger than age 18
  • Adults who are not capable of providing informed consent, individuals with conservators, or those unable to read and speak English proficiently.
State
Connecticut

Helping the Families of Treatment-Refusers

Alec Pollard, PhD

Founder and Director, Saint Louis Behavioral Medicine Institute Anxiety Disorders Center
Professor, Community and Family Medicine at Saint Louis University

Dr. Pollard gives advice to family members who live with someone who refuses treatment for OCD and anxiety disorders Dr. Pollard gives advice to family members who live with someone who refuses treatment for OCD and anxiety disorders and explains a strategy that teaches family members to shape treatment-seeking behavior in someone with an anxiety disorder.

Spread the Word

Help us spread the word about the benefits of treatment for anxiety and mood disorders, OCD, and PTSD — for children and teens, women, men, and all those suffering from related illnesses.

Please tweet, post on Facebook, or add the links to your own website — whatever works to get the word out that you are not alone and help is here!